Skip to main content
Erschienen in:

30.08.2024 | Neuro-Images

Cognitive function in Parkinson’s disease: associations with perivascular space in basal ganglia

verfasst von: Zhenglong Luo, Yangfan Zhu, Yongyun Zhu, Bin Liu, Yuxia Li, Lei Yin, Jie Liu, Zhong Xu, Hui Ren, Xinglong Yang

Erschienen in: Neurological Sciences | Ausgabe 12/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Cognitive impairment is one of the most common symptoms of Parkinson’s disease (PD), and may be detectable through changes in neural features visualized by magnetic resonance imaging (MRI). Mild cognitive impairment is a transitional state between normal aging and dementia, and early recognition of Parkinson’s disease with mild cognitive impairment (PD-MCI) can help improve the quality of life and treatment for patients. This study investigated the association of enlarged perivascular space (EPVS) and white matter hyperintensity (WMH) with PD-MCI.

Aims

This study aimed to evaluate whether EPVS and WMH can be used as potential MRI markers for PD-MCI.

Methods

This retrospective study involved 200 patients with PD who underwent cranial MRI in our hospital from April 2021 to April 2022. Patients were divided into those with no cognitive impairment (PD-NCI) or mild cognitive impairment. Uni- and multivariate logistic regression analyzed associations of EPVS, WMH, and clinicodemographic characteristics with cognitive decline.

Results

Univariate regression identified severe EPVS in basal ganglia, severe WMH, older age, late-onset, male sex, low educational level, longer duration of disease, low triglycerides, low uric acid, and low scores on the Mini-mental State Exam as risk factors for PD-MCI. After adjusting for clinicodemographic risk factors in multivariate regression, low education level and EPVS in basal ganglia remained risk factors for cognitive impairment.

Conclusions

Severe EPVS in basal ganglia and poor education, but not WMH, are independent risk factors of PD-MCI. Our findings suggest that non-invasive detection of EPVS in basal ganglia by MRI may be a valuable early indicator of cognitive decline in PD patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Coelho M et al (2015) Dementia and severity of parkinsonism determines the handicap of patients in late-stage Parkinson’s disease: the Barcelona-Lisbon cohort. Eur J Neurol 22(2):305–312PubMed Coelho M et al (2015) Dementia and severity of parkinsonism determines the handicap of patients in late-stage Parkinson’s disease: the Barcelona-Lisbon cohort. Eur J Neurol 22(2):305–312PubMed
2.
Zurück zum Zitat Yarnall AJ, Rochester L, Burn DJ (2013) Mild cognitive impairment in Parkinson’s disease. Age Ageing 42(5):567–576PubMed Yarnall AJ, Rochester L, Burn DJ (2013) Mild cognitive impairment in Parkinson’s disease. Age Ageing 42(5):567–576PubMed
3.
Zurück zum Zitat Hobson P, Meara J (2015) Mild cognitive impairment in Parkinson’s disease and its progression onto dementia: a 16-year outcome evaluation of the Denbighshire cohort. Int J Geriatr Psychiatry 30(10):1048–1055PubMed Hobson P, Meara J (2015) Mild cognitive impairment in Parkinson’s disease and its progression onto dementia: a 16-year outcome evaluation of the Denbighshire cohort. Int J Geriatr Psychiatry 30(10):1048–1055PubMed
4.
Zurück zum Zitat Hu MT et al (2014) Predictors of cognitive impairment in an early stage Parkinson’s disease cohort. Mov Disord 29(3):351–359PubMedPubMedCentral Hu MT et al (2014) Predictors of cognitive impairment in an early stage Parkinson’s disease cohort. Mov Disord 29(3):351–359PubMedPubMedCentral
5.
Zurück zum Zitat Weil RS, Costantini AA, Schrag AE (2018) Mild cognitive impairment in Parkinson’s Disease-what is it? Curr Neurol Neurosci Rep 18(4):17PubMedPubMedCentral Weil RS, Costantini AA, Schrag AE (2018) Mild cognitive impairment in Parkinson’s Disease-what is it? Curr Neurol Neurosci Rep 18(4):17PubMedPubMedCentral
6.
Zurück zum Zitat Delgado-Alvarado M et al (2016) Biomarkers for dementia and mild cognitive impairment in Parkinson’s disease. Mov Disord 31(6):861–881PubMed Delgado-Alvarado M et al (2016) Biomarkers for dementia and mild cognitive impairment in Parkinson’s disease. Mov Disord 31(6):861–881PubMed
7.
Zurück zum Zitat Hansen TP et al (2015) Dilated perivascular spaces in the basal ganglia are a biomarker of small-vessel disease in a very elderly population with dementia. AJNR Am J Neuroradiol 36(5):893–898PubMedPubMedCentral Hansen TP et al (2015) Dilated perivascular spaces in the basal ganglia are a biomarker of small-vessel disease in a very elderly population with dementia. AJNR Am J Neuroradiol 36(5):893–898PubMedPubMedCentral
8.
Zurück zum Zitat Park YW et al (2019) Magnetic resonance imaging-visible Perivascular spaces in basal Ganglia Predict Cognitive decline in Parkinson’s Disease. Mov Disord 34(11):1672–1679PubMed Park YW et al (2019) Magnetic resonance imaging-visible Perivascular spaces in basal Ganglia Predict Cognitive decline in Parkinson’s Disease. Mov Disord 34(11):1672–1679PubMed
9.
Zurück zum Zitat Shen T et al (2021) The role of brain perivascular space burden in early-stage Parkinson’s disease. NPJ Parkinsons Dis 7(1):12PubMedPubMedCentral Shen T et al (2021) The role of brain perivascular space burden in early-stage Parkinson’s disease. NPJ Parkinsons Dis 7(1):12PubMedPubMedCentral
10.
Zurück zum Zitat Prins ND et al (2005) Cerebral small-vessel disease and decline in information processing speed, executive function and memory. Brain 128(Pt 9):2034–2041PubMed Prins ND et al (2005) Cerebral small-vessel disease and decline in information processing speed, executive function and memory. Brain 128(Pt 9):2034–2041PubMed
11.
Zurück zum Zitat Dadar M et al (2020) White Matter Hyperintensities Mediate Impact of Dysautonomia on Cognition in Parkinson’s Disease. Mov Disord Clin Pract 7(6):639–647PubMedPubMedCentral Dadar M et al (2020) White Matter Hyperintensities Mediate Impact of Dysautonomia on Cognition in Parkinson’s Disease. Mov Disord Clin Pract 7(6):639–647PubMedPubMedCentral
12.
Zurück zum Zitat Hanning U et al (2019) White matter hyperintensities are not associated with cognitive decline in early Parkinson’s disease - the DeNoPa cohort. Parkinsonism Relat Disord 69:61–67PubMed Hanning U et al (2019) White matter hyperintensities are not associated with cognitive decline in early Parkinson’s disease - the DeNoPa cohort. Parkinsonism Relat Disord 69:61–67PubMed
13.
Zurück zum Zitat Postuma RB et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30(12):1591–1601PubMed Postuma RB et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30(12):1591–1601PubMed
14.
Zurück zum Zitat Litvan I et al (2012) Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord 27(3):349–356PubMedPubMedCentral Litvan I et al (2012) Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord 27(3):349–356PubMedPubMedCentral
15.
Zurück zum Zitat Emre M et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord, 22(12): p. 1689 – 707; quiz 1837. Emre M et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord, 22(12): p. 1689 – 707; quiz 1837.
16.
Zurück zum Zitat Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. J Psychiatr Res 12(3):189–198 A practical method for grading the cognitive state of patients for the clinicianPubMed Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. J Psychiatr Res 12(3):189–198 A practical method for grading the cognitive state of patients for the clinicianPubMed
17.
Zurück zum Zitat Dalrymple-Alford JC et al (2010) The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 75(19):1717–1725PubMed Dalrymple-Alford JC et al (2010) The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 75(19):1717–1725PubMed
18.
Zurück zum Zitat Wardlaw JM et al (2013) Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 12(8):822–838PubMedPubMedCentral Wardlaw JM et al (2013) Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 12(8):822–838PubMedPubMedCentral
19.
Zurück zum Zitat Doubal FN et al (2010) Enlarged perivascular spaces on MRI are a feature of cerebral small vessel disease. Stroke 41(3):450–454PubMed Doubal FN et al (2010) Enlarged perivascular spaces on MRI are a feature of cerebral small vessel disease. Stroke 41(3):450–454PubMed
20.
Zurück zum Zitat Fazekas F et al (1993) Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology 43(9):1683–1689PubMed Fazekas F et al (1993) Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology 43(9):1683–1689PubMed
21.
Zurück zum Zitat Shibata K et al (2019) The effect of small vessel disease on motor and cognitive function in Parkinson’s disease. Clin Neurol Neurosurg 182:58–62PubMed Shibata K et al (2019) The effect of small vessel disease on motor and cognitive function in Parkinson’s disease. Clin Neurol Neurosurg 182:58–62PubMed
22.
Zurück zum Zitat Chen H et al (2021) Cerebral small vessel disease may worsen motor function, cognition, and mood in Parkinson’s disease. Parkinsonism Relat Disord 83:86–92PubMed Chen H et al (2021) Cerebral small vessel disease may worsen motor function, cognition, and mood in Parkinson’s disease. Parkinsonism Relat Disord 83:86–92PubMed
23.
Zurück zum Zitat Zhu R et al (2022) Total Burden of Cerebral Small Vessel Disease on MRI May Predict Cognitive Impairment in Parkinson’s Disease. J Clin Med, 11(18) Zhu R et al (2022) Total Burden of Cerebral Small Vessel Disease on MRI May Predict Cognitive Impairment in Parkinson’s Disease. J Clin Med, 11(18)
24.
Zurück zum Zitat Ramirez J et al (2022) Small and large magnetic resonance imaging-visible Perivascular spaces in the basal ganglia of Parkinson’s Disease patients. Mov Disord 37(6):1304–1309PubMed Ramirez J et al (2022) Small and large magnetic resonance imaging-visible Perivascular spaces in the basal ganglia of Parkinson’s Disease patients. Mov Disord 37(6):1304–1309PubMed
25.
Zurück zum Zitat Rudie JD et al (2018) Neuroimaging of dilated Perivascular spaces: from Benign and Pathologic causes to Mimics. J Neuroimaging 28(2):139–149PubMed Rudie JD et al (2018) Neuroimaging of dilated Perivascular spaces: from Benign and Pathologic causes to Mimics. J Neuroimaging 28(2):139–149PubMed
26.
Zurück zum Zitat Del Tredici K, Braak H (2016) Review: sporadic Parkinson’s disease: development and distribution of α-synuclein pathology. Neuropathol Appl Neurobiol 42(1):33–50PubMed Del Tredici K, Braak H (2016) Review: sporadic Parkinson’s disease: development and distribution of α-synuclein pathology. Neuropathol Appl Neurobiol 42(1):33–50PubMed
27.
Zurück zum Zitat Stewart T et al (2014) Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am J Pathol 184(4):966–975PubMedPubMedCentral Stewart T et al (2014) Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am J Pathol 184(4):966–975PubMedPubMedCentral
28.
Zurück zum Zitat Lin CH et al (2017) Plasma α-synuclein predicts cognitive decline in Parkinson’s disease. J Neurol Neurosurg Psychiatry 88(10):818–824PubMed Lin CH et al (2017) Plasma α-synuclein predicts cognitive decline in Parkinson’s disease. J Neurol Neurosurg Psychiatry 88(10):818–824PubMed
29.
Zurück zum Zitat Shahid M et al (2019) An increased rate of longitudinal cognitive decline is observed in Parkinson’s disease patients with low CSF Aß42 and an APOE ε4 allele. Neurobiol Dis 127:278–286PubMedPubMedCentral Shahid M et al (2019) An increased rate of longitudinal cognitive decline is observed in Parkinson’s disease patients with low CSF Aß42 and an APOE ε4 allele. Neurobiol Dis 127:278–286PubMedPubMedCentral
31.
Zurück zum Zitat Iliff JJ et al (2012) A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med 4(147):147ra111PubMedPubMedCentral Iliff JJ et al (2012) A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med 4(147):147ra111PubMedPubMedCentral
32.
Zurück zum Zitat Bobela W, Aebischer P, Schneider BL (2015) Αlpha-Synuclein as a Mediator in the interplay between Aging and Parkinson’s Disease. Biomolecules 5(4):2675–2700PubMedPubMedCentral Bobela W, Aebischer P, Schneider BL (2015) Αlpha-Synuclein as a Mediator in the interplay between Aging and Parkinson’s Disease. Biomolecules 5(4):2675–2700PubMedPubMedCentral
33.
Zurück zum Zitat Zou W et al (2019) Blocking meningeal lymphatic drainage aggravates Parkinson’s disease-like pathology in mice overexpressing mutated α-synuclein. Transl Neurodegener 8:7PubMedPubMedCentral Zou W et al (2019) Blocking meningeal lymphatic drainage aggravates Parkinson’s disease-like pathology in mice overexpressing mutated α-synuclein. Transl Neurodegener 8:7PubMedPubMedCentral
34.
Zurück zum Zitat Hawkes CA et al (2012) Disruption of arterial perivascular drainage of amyloid-β from the brains of mice expressing the human APOE ε4 allele. PLoS ONE 7(7):e41636PubMedPubMedCentral Hawkes CA et al (2012) Disruption of arterial perivascular drainage of amyloid-β from the brains of mice expressing the human APOE ε4 allele. PLoS ONE 7(7):e41636PubMedPubMedCentral
35.
Zurück zum Zitat Peng W et al (2016) Suppression of glymphatic fluid transport in a mouse model of Alzheimer’s disease. Neurobiol Dis 93:215–225PubMedPubMedCentral Peng W et al (2016) Suppression of glymphatic fluid transport in a mouse model of Alzheimer’s disease. Neurobiol Dis 93:215–225PubMedPubMedCentral
36.
Zurück zum Zitat Rasmussen MK, Mestre H, Nedergaard M (2018) The glymphatic pathway in neurological disorders. Lancet Neurol 17(11):1016–1024PubMedPubMedCentral Rasmussen MK, Mestre H, Nedergaard M (2018) The glymphatic pathway in neurological disorders. Lancet Neurol 17(11):1016–1024PubMedPubMedCentral
37.
Zurück zum Zitat Ramirez J et al (2016) Imaging the Perivascular Space as a potential biomarker of neurovascular and neurodegenerative diseases. Cell Mol Neurobiol 36(2):289–299PubMed Ramirez J et al (2016) Imaging the Perivascular Space as a potential biomarker of neurovascular and neurodegenerative diseases. Cell Mol Neurobiol 36(2):289–299PubMed
38.
Zurück zum Zitat Donahue EK et al (2021) Global and Regional changes in Perivascular Space in Idiopathic and Familial Parkinson’s Disease. Mov Disord 36(5):1126–1136PubMedPubMedCentral Donahue EK et al (2021) Global and Regional changes in Perivascular Space in Idiopathic and Familial Parkinson’s Disease. Mov Disord 36(5):1126–1136PubMedPubMedCentral
39.
Zurück zum Zitat Brown R et al (2018) Understanding the role of the perivascular space in cerebral small vessel disease. Cardiovasc Res 114(11):1462–1473PubMedPubMedCentral Brown R et al (2018) Understanding the role of the perivascular space in cerebral small vessel disease. Cardiovasc Res 114(11):1462–1473PubMedPubMedCentral
40.
Zurück zum Zitat Li Y et al (2019) The relationship between blood-brain barrier permeability and enlarged perivascular spaces: a cross-sectional study. Clin Interv Aging 14:871–878PubMedPubMedCentral Li Y et al (2019) The relationship between blood-brain barrier permeability and enlarged perivascular spaces: a cross-sectional study. Clin Interv Aging 14:871–878PubMedPubMedCentral
41.
Zurück zum Zitat Montagne A et al (2018) Pericyte degeneration causes white matter dysfunction in the mouse central nervous system. Nat Med 24(3):326–337PubMedPubMedCentral Montagne A et al (2018) Pericyte degeneration causes white matter dysfunction in the mouse central nervous system. Nat Med 24(3):326–337PubMedPubMedCentral
42.
Zurück zum Zitat Sweeney MD et al (2018) The role of brain vasculature in neurodegenerative disorders. Nat Neurosci 21(10):1318–1331PubMedPubMedCentral Sweeney MD et al (2018) The role of brain vasculature in neurodegenerative disorders. Nat Neurosci 21(10):1318–1331PubMedPubMedCentral
43.
Zurück zum Zitat Rektor I et al (2009) Vascular pathology in patients with idiopathic Parkinson’s disease. Parkinsonism Relat Disord 15(1):24–29PubMed Rektor I et al (2009) Vascular pathology in patients with idiopathic Parkinson’s disease. Parkinsonism Relat Disord 15(1):24–29PubMed
44.
Zurück zum Zitat Doiron M et al (2018) The influence of vascular risk factors on cognitive function in early Parkinson’s disease. Int J Geriatr Psychiatry 33(2):288–297PubMed Doiron M et al (2018) The influence of vascular risk factors on cognitive function in early Parkinson’s disease. Int J Geriatr Psychiatry 33(2):288–297PubMed
45.
Zurück zum Zitat Sunwoo MK et al (2014) The burden of white matter hyperintensities is a predictor of progressive mild cognitive impairment in patients with Parkinson’s disease. Eur J Neurol 21(6):922–e50PubMed Sunwoo MK et al (2014) The burden of white matter hyperintensities is a predictor of progressive mild cognitive impairment in patients with Parkinson’s disease. Eur J Neurol 21(6):922–e50PubMed
46.
Zurück zum Zitat Dadar M et al (2018) White matter hyperintensities are linked to future cognitive decline in de novo Parkinson’s disease patients. Neuroimage Clin 20:892–900PubMedPubMedCentral Dadar M et al (2018) White matter hyperintensities are linked to future cognitive decline in de novo Parkinson’s disease patients. Neuroimage Clin 20:892–900PubMedPubMedCentral
Metadaten
Titel
Cognitive function in Parkinson’s disease: associations with perivascular space in basal ganglia
verfasst von
Zhenglong Luo
Yangfan Zhu
Yongyun Zhu
Bin Liu
Yuxia Li
Lei Yin
Jie Liu
Zhong Xu
Hui Ren
Xinglong Yang
Publikationsdatum
30.08.2024
Verlag
Springer International Publishing
Erschienen in
Neurological Sciences / Ausgabe 12/2024
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-024-07729-9

Kompaktes Leitlinien-Wissen Neurologie (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Neurologie

Ehe schützt nicht vor Demenz

  • 25.04.2025
  • Demenz
  • Nachrichten

Eigentlich leben Verheiratete länger und gesünder. Eine aktuelle Untersuchung kommt jedoch zu dem überraschenden Schluss, dass sie eher an Demenz erkranken als nie Verheiratete, Geschiedene oder Verwitwete.

Lohnt sich die Karotis-Revaskularisation?

Die medikamentöse Therapie für Menschen mit Karotisstenosen hat sich in den vergangenen Dekaden verbessert. Braucht es also noch einen invasiven Eingriff zur Revaskularisation der Halsschlagader bei geringem bis moderatem Risiko für einen ipsilateralen Schlaganfall?

Neuartige Antikörpertherapie bremst MS über zwei Jahre hinweg

Eine Therapie mit dem C40-Ligand-Blocker Frexalimab kann MS-Schübe und neue MRT-Läsionen über zwei Jahre hinweg verhindern. Dafür spricht die Auswertung einer offen fortgeführten Phase-2-Studie.

Therapiestopp bei älteren MS-Kranken kann sich lohnen

Eine Analyse aus Kanada bestätigt: Setzen ältere MS-Kranke die Behandlung mit Basistherapeutika ab, müssen sie kaum mit neuen Schüben und MRT-Auffälligkeiten rechnen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.